Jaap Blaak

VenGen BV is an independent venture capital investment firm based in Amsterdam. VenGen was founded in 2001 by Alfred Nijkerk, Bart van den Berg and Jaap Blaak. The firm's name is short for 'venture genesis' or rather the origin of venture. The firm provides venture capital to scientists and entrepreneurs operating in the field of life sciences.

TAilWind BV provides financial and investment services to biotechnology companies. The company was founded by Jaap Blaak in 1995 and is headquartered in Wassenaar, Netherlands.

VenGen Holding BV provides investment services. The private company is based in Amsterdam, Netherlands. and has subsidiaries in Netherlands. The Dutch company was founded by Jaap Blaak.

FlexGen Holding BV produces micro-arrays with the use of lasers in the synthesis of oligonucleotides. The company was founded in 2004 and is headquartered in Leiden, the Netherlands.

Janssen Biologics BV manufactures, acquires and markets biopharmaceutical therapies. The firms products focus on cardiovascular and immunological disorders, and cancer. The company was founded in 1984 and is headquartered in Leiden, the Netherlands.

to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands.

Piculet Biosciences BV develops and markets oligonucleotide binding moieties for pharmaceutical applications. The firm’s oligonucleotide synthesis system combines pace derived hardware engineering with biochemistry and nucleotide photo-deprotection technology into an integrated bench-top instrument for oligonucleotide production. The company was founded in December 2004 and is headquartered in Leiden, the Netherlands.

BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands.